Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ • Healthcare

$10.53

-$0.12 (-1.1%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$10.58

Previous Close$10.53

Day Range$10.07 - $10.65

Avg. Volume (3M)1.1M

Market Cap$885.7M

52 Week Range

$6.39$26.95

Next EarningsIn 9 daysNov 3, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$54.1M

EPS (TTM)

-$0.64

ROA (TTM)

-22.62%

Current Ratio

16.16

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+23.1%Q3 2025-$0.1

+14.3%Q4 2025-$0.12

-7.1%Q1 2026-$0.15

-7.1%Q2 2026-$0.15

-19.4%Q3 2026-$0.19

Nov 3

in 9 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -19.4%

Corvus Pharmaceuticals’ earnings missed expectations in the second fiscal quarter of 2026, with EPS of -$0.19 trailing the -$0.16 estimate by -$0.03; the company reported these preliminary results on August 6, 2026. Net income was a loss of about $18.0 million, down ~125% from roughly $8.0 million a year ago, as the period also produced operating income of around -$19.3 million. EPS was down ~90% from -$0.10 a year ago. Cash flow from operations was negative at about $15.4 million, reflecting ongoing spend across its immuno-oncology and related pipeline programs, including mupadolimab (CPI-006), CPI-818, and ciforadenant (CPI-444). For the next period, consensus calls for EPS of -$0.21.

Next report — what to expect

Corvus Pharmaceuticals, Inc. (CRVS) is set to report earnings on November 3, 2026. Wall Street’s next-period consensus calls for EPS of -$0.192. The company has beaten EPS expectations in 2 of its 8 most recent quarters, making EPS versus consensus a key item to watch in the release.

View full earnings history

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on developing and commercializing immuno-oncology therapies. The company operates as a small-cap drug developer built around antibody and small-molecule candidates, with programs aimed at cancer as well as inflammatory and fibrotic disease pathways.

Name

Corvus Pharmaceuticals, Inc.

CEO

Richard A. Miller

Website

www.corvuspharma.com

Industry

Healthcare

Year Founded

2014

Employees

Today's Snapshot

AI-generated

CRVS closed 1.1% below yesterday's close, in line with a weaker sector. Earnings are due from CRVS on 3 November.

Trading Volume

Below 10d avg (1.0M)

933.6K

vs S&P 500 Today

Underperforming Market

-0.61%

Updated: October 23, 2026 at 20:22 UTC

Technical Indicators

1 Buy3 Neutral4 Sell

CRVS signals a Sell stance reflecting a combination of downward trend readings and elevated volatility. ADX points to a discernible trend, and multiple medium-to-long-term moving averages sit above the current price, indicating broader weakness despite short-term averages trading near the market. ATR is relatively high as a percentage, implying larger recent price swings, and on-balance volume is negative, consistent with distribution. Momentum and oscillator readings are neutral to slightly bearish, offering limited support for a rebound. Technical takeaway: Sell — trend and volume favor lower prices.

All signals

EMA (5 indicators)$10.23 - $12.79
Sell
RSI (14)45.15
Neutral
Stochastic %K (14, 3, 3)64.32
Neutral
MACD Level (12, 26)-0.62
Neutral

Peers & Related Assets

RCUSArcus Biosciences, Inc.

$18.54-4.2%

CHRSCoherus Oncology, Inc.

$1.01-3.8%

CMPXCompass Therapeutics, Inc.

$0.76-5.0%

NKTRNektar Therapeutics

CTMXCytomX Therapeutics, Inc.

CGENCompugen Ltd.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.